Top

Published in:

01-03-2011

Cost-effectiveness of varenicline and three different behavioral treatment formats for smoking cessation

Authors: Harold S Javitz, PhD, Susan M Zbikowski, PhD, Mona Deprey, MS, Timothy A McAfee, MD, MPH, Jennifer B McClure, PhD, Julie Richards, MPH, Sheryl L Catz, PhD, Lisa M Jack, MA, Gary E Swan, PhD

Published in: Translational Behavioral Medicine | Issue 1/2011

Abstract

There is a lack of evidence of the relative cost-effectiveness of proactive telephone counseling (PTC) and Web-based delivery of smoking cessation services in conjunction with pharmacotherapy. We calculated the differential cost-effectiveness of three behavioral smoking cessation modalities with varenicline treatment in a randomized trial of current smokers from a large health system. Eligible participants were randomized to one of three smoking cessation interventions: Web-based counseling (n = 401), PTC (n = 402), or combined PTC-Web counseling (n = 399). All participants received a standard 12-week course of varenicline. The primary outcome was a 7-day point prevalent nonsmoking at the 6 month follow-up. The Web intervention was the least expensive followed by the PTC and PTC-Web groups. Costs per additional 6-month nonsmoker and per additional lifetime quitter were $1,278 and $2,601 for Web, $1,472 and $2,995 for PTC, and $1,617 and $3,291 for PTC-Web. Cost per life-year (LY) and quality-adjusted life-year (QALY) saved were $1,148 and $1,136 for Web, $1,320 and $1,308 for PTC, and $1,450 and $1,437 for PTC-Web. Based on the cost per LY and QALY saved, these interventions are among the most cost-effective life-saving medical treatments. Web, PTC, and combined PTC-Web treatments were all highly cost-effective, with the Web treatment being marginally more cost-effective than the PTC or combined PTC-Web treatments.

Fiore, M.C., et al. Treating Tobacco Use and Dependence: 2008 Update, in Clinical Practice Guideline. May 2008, U.S. Department of Health and Human Services. Public Health Service: Clinical Practice Guideline. Rockville, MD.

Stead, L. F., Perera, R., & Lancaster, T. (2006). Telephone counselling for smoking cessation. Cochrane Database Of Systematic Reviews, 3, CD002850.

Cobb, N. K., et al. (2005). Initial evaluation of a real-world Internet smoking cessation system. Nicotine & Tobacco Research, 7(2), 207–216.CrossRef

Graham, A. L., et al. (2007). Effectiveness of an internet-based worksite smoking cessation intervention at 12 months. Journal of Occupational and Environmental Medicine, 49(8), 821–828.PubMedCrossRef

Saul, J. E., et al. (2007). Impact of a statewide Internet-based tobacco cessation intervention. Journal of Medical Internet Research, 9(3), e28.PubMedCrossRef

Etter, J. F. (2005). Comparing the efficacy of two Internet-based, computer-tailored smoking cessation programs: a randomized trial. Journal of Medical Internet Research, 7(1), e2.PubMedCrossRef

Japuntich, S. J., et al. (2006). Smoking cessation via the internet: a randomized clinical trial of an internet intervention as adjuvant treatment in a smoking cessation intervention. Nicotine Tob Res, 8(Suppl 1), S59–S67.PubMedCrossRef

Pike, K. J., et al. (2007). American Cancer Society's QuitLink: randomized trial of Internet assistance. Nicotine & Tobacco Research, 9(3), 415–420.CrossRef

Strecher, V. J., et al. (2008). Web-based smoking-cessation programs: results of a randomized trial. American Journal of Preventive Medicine, 34(5), 373–381.PubMedCrossRef

10.

Strecher, V. J., Shiffman, S., & West, R. (2005). Randomized controlled trial of a Web-based computer-tailored smoking cessation program as a supplement to nicotine patch therapy. Addiction, 100(5), 682–688.PubMedCrossRef

11.

Cahill, K., Stead, L. F., & Lancaster, T. (2007). Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews, 1, CD006103.

12.

Nides, M., et al. (2006). Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Archives of Internal Medicine, 166(15), 1561–1568.PubMedCrossRef

13.

Oncken, C., et al. (2006). Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Archives of Internal Medicine, 166(15), 1571–1577.PubMedCrossRef

14.

Niaura, R., et al. (2008). The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Current Medical Research and Opinion, 24(7), 1931–1941.PubMedCrossRef

15.

Gonzales, D., et al. (2006). Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. Journal of the American Medical Association, 296(1), 47–55.PubMedCrossRef

16.

Jorenby, D. E., et al. (2006). Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. Journal of the American Medical Association, 296(1), 56–63.PubMedCrossRef

17.

Nakamura, M., et al. (2007). Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clinical Therapeutics, 29(6), 1040–1056.PubMedCrossRef

18.

Tsai, S. T., et al. (2007). A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clinical Therapeutics, 29(6), 1027–1039.PubMedCrossRef

19.

Tonstad, S., et al. (2006). Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. Journal of the American Medical Association, 296(1), 64–71.PubMedCrossRef

20.

Hollis, J. F., et al. (2007). The effectiveness and cost effectiveness of telephone counselling and the nicotine patch in a state tobacco quitline. Tobacco Control, 16(Suppl 1), i53–i59.PubMedCrossRef

21.

Orleans, C. T., et al. (1991). Self-help quit smoking interventions: effects of self-help materials, social support instructions, and telephone counseling. Journal of Consulting and Clinical Psychology, 59(3), 439–448.PubMedCrossRef

22.

Swan, G. E., et al. (2003). Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. Archives of Internal Medicine, 163(19), 2337–2344.PubMedCrossRef

23.

Curry, S. J., et al. (1998). Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization. The New England Journal of Medicine, 339(10), 673–679.PubMedCrossRef

24.

Ringen, K., et al. (2002). Smoking cessation in a blue-collar population: results from an evidence-based pilot program. American Journal of Industrial Medicine, 42(5), 367–377.PubMedCrossRef

25.

McClure, J. B., et al. (2009). Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. Journal of General Internal Medicine, 24(5), 563–569.PubMedCrossRef

26.

Swan, G. E., et al. (2010). Behavioral counseling and varenicline treatment for smoking cessation. American Journal of Preventive Medicine, 38(5), 482–490.PubMedCrossRef

27.

Velicer, W. F., et al. (1992). Assessing outcome in smoking cessation studies. Psychological Bulletin, 111(1), 23–41.PubMedCrossRef

28.

Patrick, D. L., et al. (1994). The validity of self-reported smoking: a review and meta-analysis. American Journal of Public Health, 84(7), 1086–1093.PubMedCrossRef

29.

Gorber, S., et al. (2009). The accuracy of self-reported smoking: a systematic review of the relationship between self-reported and cotinine-assessed smoking status. Nicotine & Tobacco Research, 11(1), 12–24.CrossRef

30.

Swan, G. E., et al. (1993). Cardiovascular reactivity as a predictor of relapse in male and female smokers. Health Psychology, 12(6), 451–458.PubMedCrossRef

31.

Garrison, G.D. and S.E. Dugan, Varenicline: a first-line treatment option for smoking cessation. Clin Ther, Mar 2009. 31(3).

32.

Fiscella, K., & Franks, P. (1996). Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. Journal of the American Medical Association, 275(16), 1247–1251.PubMedCrossRef

33.

Stapleton, J. A., Lowin, A., & Russell, M. A. (1999). Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectiveness. Lancet, 354(9174), 210–215.PubMedCrossRef

34.

Etter, J. F., & Stapleton, J. A. (2006). Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. Tobacco Control, 15, 280–285.PubMedCrossRef

35.

Javitz, H. S., et al. (2004). Cost-effectiveness of different combinations of bupropion SR dose and behavioral treatment for smoking cessation: a societal perspective. American Journal of Managed Care, 10(3), 217–226.PubMed

36.

Wasley, M. A., et al. (1997). The cost-effectiveness of the nicotine transdermal patch for smoking cessation. Preventive Medicine, 26(2), 264–270.PubMedCrossRef

37.

Oster, G., et al. (1986). Cost-effectiveness of nicotine gum as an adjunct to physician's advice against cigarette smoking. Journal of the American Medical Association, 256(10), 1315–1318.PubMedCrossRef

38.

Centers for Disease Control and Prevention, Smoking cessation during previous year among adults—United States, 1990 and 1991. MMWR Morb Mortal Wkly Rep, 1993. 42: p. 504–7

39.

Croghan, I. T., et al. (1997). Cost-effectiveness of treating nicotine dependence: the Mayo clinic experience. Mayo Clinic Proceedings, 72(10), 917–924.PubMedCrossRef

40.

Centers for Disease Control and Prevention, Years of healthy life. Stat Notes, 1995. 7: p. 1–14.

41.

White, I.R. and J.B. Carlin, Bias and efficiency of multiple imputation compared with complete-case analysis for missing values. Stat Med (Epub ahead of print), 2010.

42.

Barnes, S. A., et al. (2010). Missing data assumptions and methods in smoking cessation. Addiction, 105(3), 431–437.PubMedCrossRef

43.

Solberg, L. I., et al. (2006). Repeated tobacco-use screening and intervention in clinical practice. American Journal of Preventive Medicine, 31(1), 62–71.PubMedCrossRef

44.

Rogers, R. G., & Powell-Griner, E. (1991). Life expectancies of cigarette smokers and nonsmokers in the United States. Social Science & Medicine, 32, 1151–1159.CrossRef

45.

Taylor, D. H., et al. (2002). Benefits of smoking cessation for longevity. American Journal of Public Health, 92, 990–996.PubMedCrossRef

46.

Centers for Disease Control and Prevention, Behavorial Risk Factor Surveillance System, in available at: www.cdc.gov/brfss/. Accessed on: June 13, 2005. 2003.

47.

Wu, P., et al. (2006). Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health, 6, 300–315.PubMedCrossRef

48.

Bolin, K., et al. (2009). Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation-results from four European countries. European Journal of Pub Health, 19(6), 650–654.CrossRef

49.

Knight, H. P., Boler, A., & Baker, C. (2008). Cost-utility analysis of varenciline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. Pharmacoeconomics, 26(6), 497–511.PubMedCrossRef

50.

Faulkner, M. A. (2009). Smoking cessation: an economic analysis and review of varenicline. Clinico Econ Outcomes Res, 1, 25–34.CrossRef

51.

Leu, R. E., & Schaub, T. (1983). Does smoking increase medical care expenditure? Social Science & Medicine, 17(23), 1907–1914.CrossRef

52.

Tengs, T. O., et al. (1995). Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis, 15(3), 369–390.PubMedCrossRef

53.

Cheung, A. M., & Tsevat, J. (1997). Economic evaluations of smoking interventions. Preventive Medicine, 26(2), 271–273.PubMedCrossRef

54.

Tsevat, J. (1992). Impact and cost-effectiveness of smoking interventions. American Journal of Medicine, 93(1A), 43S–47S.PubMedCrossRef

55.

Weinstein, M. C., & Stason, W. B. (1985). Cost-effectiveness of interventions to prevent or treat coronary heart disease. Annual Review of Public Health, 6, 41–63.PubMedCrossRef

56.

Warner, K. E. (1997). Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence-and implications for coverage. PharmacoEconomics, 11(6), 538–549.PubMedCrossRef

57.

Mendez, D., Warner, K. E., & Courant, P. N. (1998). Has smoking cessation ceased? Expected trends in the prevalence of smoking in the United States. American Journal of Epidemiology, 148, 249–258.PubMed

Title: Cost-effectiveness of varenicline and three different behavioral treatment formats for smoking cessation
Authors: Harold S Javitz, PhD
Susan M Zbikowski, PhD
Mona Deprey, MS
Timothy A McAfee, MD, MPH
Jennifer B McClure, PhD
Julie Richards, MPH
Sheryl L Catz, PhD
Lisa M Jack, MA
Gary E Swan, PhD
Publication date: 01-03-2011
Publisher: Springer-Verlag
Published in: Translational Behavioral Medicine / Issue 1/2011
Print ISSN: 1869-6716
Electronic ISSN: 1613-9860
DOI: https://doi.org/10.1007/s13142-010-0009-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cost-effectiveness of varenicline and three different behavioral treatment formats for smoking cessation

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Nudging best practice: the HITECH act and behavioral medicine

CYberinfrastructure for COmparative effectiveness REsearch (CYCORE): improving data from cancer clinical trials

News from the CDC

Translational Behavioral Medicine: a pathway to better health

Adapting research-tested computerized tailored interventions for broader dissemination and implementation

If we only knew what we know: principles for knowledge sharing across people, practices, and platforms